You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Automated SCAP Tool Validator (ASTV)

    SBC: ATC-NY INC            Topic: 9010377R

    The current testing methods of the NIST Security Content Automation Protocol (SCAP) Validation Program are largely manual and labor-intensive, making comprehensive validation of SCAP-enabled IT security products difficult and time-consuming. ATC-NY will design and develop the Automated SCAP Tool Validator (ASTV) for use with the SCAP Public Validation Test Suite and others. ASTV automates the conf ...

    SBIR Phase I 2013 Department of CommerceNational Institute of Standards and Technology
  2. Surveying Earth's Gravity with Unmanned Aerial Vehicles

    SBC: AURORA FLIGHT SCIENCES CORPORATION            Topic: 912RN

    To assist with the National Geodetic Survey’s federal mandate to provide accurate positioning—including heights—to all federal non-military mapping activities in the USA, Aurora Flight Sciences proposes to integrate a gravimetry payload on a unmanned aerial system (UAS). Potential options include using either an unmanned aerial vehicle (UAV) or an optionally piloted aircraft (OPA). An OPA ...

    SBIR Phase I 2013 Department of CommerceNational Oceanic and Atmospheric Administration
  3. Porous Membrane Electrode for Quantitative Detection of Toxins

    SBC: Mercury Science Inc.            Topic: 816N

    In Phase I, a novel porous electrode was designed to demonstrate a rapid, simple assay for the detection of domoic acid in marine samples. During Phase II, methods to manufacture porous electrodes will be improved to enable high volume production of low-cost biosensors that can be connected to a potentiostat. These biosensors will be incorporated into a portable test kit for the quantitation of do ...

    SBIR Phase II 2013 Department of CommerceNational Oceanic and Atmospheric Administration
  4. Dip and Read Nanosensor for Calcium Ion Measurements in Sea Water

    SBC: Polestar Technologies, Inc.            Topic: 822R

    This topic requires the capability for enabling high sensitivity/high precision measurements of calcium concentrates in seawater. This proposal aims to demonstrate the feasibility of a novel high sensitive nanosensor that can be used to determine very low concentrations of calcium in seawater in the presence of a large background calcium concentration. The sensor approach uses the benefits of nano ...

    SBIR Phase II 2013 Department of CommerceNational Oceanic and Atmospheric Administration
  5. Nomethiazoles Harnessing GABA and NO mimetic activity for Alzheimer's therapy

    SBC: sGC Pharma Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) occurs in one out of eight Americans of age 65 and affects 43% of the elderly over 85. Current FDA-approved drugs only provide symptomatic relief of AD. There is a pressing need to discover newdisease-modifying medications. AD is multifactorial in origin and progression. A drug attenuating several underlying factors is a preferred ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Insulin Pathway Agonist for Alzheimer's Disease

    SBC: MEDCHEM PARTNERS LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Even though the association of -amyloid peptide (A ) deposition and Alzheimer's Disease (AD) underpins the major hypothesis for disease progression and possibly causation and several drugs addressing the formation or removal of -amyloid plaques have entered clinical trials, no effective therapy exists to date for AD. This reality calls for new targets th ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Osteochondral tissue repair in an ovine model using a 3D woven poly (e-caprolacto

    SBC: Cytex Therapeutics, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Standard microfracture is a first-line, widely used and cost-effective surgical technique for repairing damaged articular cartilage, but, it is limited by decreased long-term efficacy and limited applicability in largerlesions. This leads to a burgeoning economic burden associated with primary and follow-up treatment costs, estimated at more than 40 billion dol ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Controlling mechanical signal transduction to treat osteoarthritis

    SBC: Cytex Therapeutics, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Controlling mechanical signal transduction to treat osteoarthritis Abstract The TRPV4 calcium (Ca++) permeable ion channel has been shown to be expressed and functional in chondrocytes, the cells responsible for the maintenance of cartilage in weight-bearing joints. Trauma of joints with subsequent damage of cartilage, as well as chronically increased joint loa ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluation of a new class of molecules for treating MRSA infective endocarditis

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Patients with infective endocarditis (IE) have a poor prognosis with one third of the patients succumbing to the infection within the first year. Treatments for endocarditis involve antibiotic therapy and/or surgery that cost upwards of 100,000 per patient; however, many cases do not respond to the antibiotic treatment and surgery poses high risks. Cases of en ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting c-Myc and Akt with PP2A reactivation therapy for the treatment of breas

    SBC: ONCOTIDE PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Each year in the United States over 270,000 women will be diagnosed with breast cancer and over 40,000 will die from the disease. While multiple forms of breast cancer exist, a common theme in most of the forms involvesaberrations in signal transduction pathways that lead to inhibition of the programmed cell death process known as apoptosis. Apoptosis is a care ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government